{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:23:54Z","timestamp":1790051034514,"version":"4.0.1"},"reference-count":262,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The field of cancer immunotherapy has evolved rapidly, offering new treatment paradigms by harnessing the body\u2019s own immune system to target and destroy malignancies. Various immunotherapeutic approaches, including immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, cytokine therapies, and oncolytic viruses, have shown significant promise in treating different cancer types. This review provides a comprehensive examination of the historical development and recent advances in cancer immunotherapy. We discuss the mechanisms of action of key immunotherapeutic modalities, along with their clinical applications and innovative delivery techniques. In particular, we focus on immune checkpoint inhibitors, which have revolutionized the treatment of several cancers; CAR-T cell therapy, which has provided transformative results in hematological malignancies; and the potential of cancer vaccines, cytokine therapies, and oncolytic viruses. Additionally, the review addresses the current status of clinical trials and patents in the field, offering insight into the ongoing efforts to optimize these therapies for broader clinical use. Despite the promising results achieved, this review highlights significant challenges, such as immune-mediated toxicity, resistance to treatment, and the need for more effective delivery systems. While cancer immunotherapy has shown great potential in improving patient outcomes, overcoming existing obstacles such as toxicity and resistance remains a major challenge. This review offers a comprehensive overview of the state of cancer immunotherapy while also providing perspectives on its future directions and the ways in which these innovations may impact cancer treatment.<\/jats:p>","DOI":"10.1186\/s43046-025-00319-6","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T23:02:50Z","timestamp":1759100570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions"],"prefix":"10.1186","volume":"37","author":[{"given":"Mahalakshmi","family":"Devaraji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binoy","family":"Varghese Cheriyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"319_CR1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-23-0411","author":"JS Brown","year":"2023","unstructured":"Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the Definition of Cancer. Molecular Cancer Research. 2023;21https:\/\/doi.org\/10.1158\/1541-7786.MCR-23-0411","journal-title":"Mol Cancer Res"},{"key":"319_CR2","doi-asserted-by":"crossref","unstructured":"Can G. Cancer basics. Medical Nursing. 2023.","DOI":"10.52305\/MRFQ5551"},{"key":"319_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211034366","author":"DT Debela","year":"2021","unstructured":"Debela DT, Muzazu SGY, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021.https:\/\/doi.org\/10.1177\/20503121211034366","journal-title":"SAGE Open Med"},{"key":"319_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.404","author":"JS McCune","year":"2016","unstructured":"McCune JS. Immunotherapy to Treat Cancer. Clin Pharmacol Ther. 2016.https:\/\/doi.org\/10.1002\/cpt.404","journal-title":"Clin Pharmacol Ther"},{"key":"319_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.985","author":"JS McCune","year":"2018","unstructured":"McCune JS. Rapid Advances in Immunotherapy to Treat Cancer. Clin Pharmacol Ther. 2018.https:\/\/doi.org\/10.1002\/cpt.985","journal-title":"Clin Pharmacol Ther"},{"key":"319_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-019-0359-6","author":"DA Boardman","year":"2019","unstructured":"Boardman DA, Levings MK. Cancer immunotherapies repurposed for use in autoimmunity. Nat Biomed Eng. 2019.https:\/\/doi.org\/10.1038\/s41551-019-0359-6","journal-title":"Nat Biomed Eng"},{"key":"319_CR7","unstructured":"American Cancer Society. How immunotherapy is used to treat cancer. American Cancer Society. 2019;"},{"key":"319_CR8","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.985376","author":"M Amin","year":"2015","unstructured":"Amin M, Lockhart AC. The potential role of immunotherapy to treat colorectal cancer. Expert Opin Investig Drugs. 2015.https:\/\/doi.org\/10.1517\/13543784.2015.985376","journal-title":"Expert Opin Investig Drugs"},{"key":"319_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-022-07525-8","author":"SL Gupta","year":"2022","unstructured":"Gupta SL, Basu S, Soni V, Jaiswal RK. Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep. 2022.https:\/\/doi.org\/10.1007\/s11033-022-07525-8","journal-title":"Mol Biol Rep"},{"key":"319_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2019.11.010","author":"N Taefehshokr","year":"2020","unstructured":"Taefehshokr N, Baradaran B, Baghbanzadeh A, Taefehshokr S. Promising approaches in cancer immunotherapy. Immunobiology. 2020. https:\/\/doi.org\/10.1016\/j.imbio.2019.11.010","journal-title":"Immunobiology"},{"key":"319_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology. 2022.https:\/\/doi.org\/10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"319_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020.https:\/\/doi.org\/10.1038\/s41467-020-17670-y","journal-title":"Nat Commun"},{"key":"319_CR13","unstructured":"Basudan AM. The role of immune checkpoint inhibitors in cancer therapy. Clin Pract. 2023."},{"key":"319_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115688","author":"AC Uscanga-Palomeque","year":"2023","unstructured":"Uscanga-Palomeque AC, Ch\u00e1vez-Escamilla AK, Alvizo-B\u00e1ez CA, Saavedra-Alonso S, Terrazas-Armend\u00e1riz LD, Tamez-Guerra RS, et al. CAR-T-Cell Therapy: From the Shop to Cancer Therapy. Int J Mol Sci. 2023.https:\/\/doi.org\/10.3390\/ijms242115688","journal-title":"Int J Mol Sci"},{"key":"319_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172159","author":"M Kaczmarek","year":"2023","unstructured":"Kaczmarek M, Pozna\u0144ska J, Fechner F, Michalska N, Paszkowska S, Napiera\u0142a A, et al. Cancer Vaccine Therapeutics: Limitations and Effectiveness\u2014A Literature Review. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12172159","journal-title":"Cells"},{"key":"319_CR16","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S308578","author":"Y Qiu","year":"2021","unstructured":"Qiu Y, Su M, Liu L, Tang Y, Pan Y, Sun J. Clinical application of cytokines in cancer immunotherapy. Drug Des Devel Ther. 2021.https:\/\/doi.org\/10.2147\/DDDT.S308578","journal-title":"Drug Des Devel Ther"},{"key":"319_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3043856","author":"S Lee","year":"2011","unstructured":"Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011.https:\/\/doi.org\/10.3390\/cancers3043856","journal-title":"Cancers (Basel)"},{"key":"319_CR18","unstructured":"Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Wspolczesna Onkologia. 2017;2."},{"key":"319_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0571-0","author":"JM Redman","year":"2016","unstructured":"Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC Med. 2016.https:\/\/doi.org\/10.1186\/s12916-016-0571-0","journal-title":"BMC Med"},{"key":"319_CR20","unstructured":"Xabier Mielgo-Rubio EAULQCMSM. Immunotherapy in non-small cell lung cancer: update and new insights. J Clin Transl Res. 2021."},{"key":"319_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-021-00764-8","author":"E Salzer","year":"2021","unstructured":"Salzer E, Attarbaschi A. The value of immunotherapy in pediatric leukemia and lymphoma. Memo - Magazine of European Medical Oncology. 2021.https:\/\/doi.org\/10.1007\/s12254-021-00764-8","journal-title":"memo"},{"key":"319_CR22","doi-asserted-by":"crossref","unstructured":"Scott\u00e9 F, Ratta R, Beuzeboc P. Side effects of immunotherapy. Curr Opin Oncol. 2019;31.","DOI":"10.1097\/CCO.0000000000000541"},{"key":"319_CR23","unstructured":"Hronek J. Research is needed to better understand combination immunotherapy side effects. ONS Voice. 2020;35."},{"key":"319_CR24","unstructured":"Leana Huntley TE. Understanding immunotherapy side effects. NCCN Guidlelines for Patients. 2020;"},{"key":"319_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jormas.2025.102265","author":"P Arumugam","year":"2025","unstructured":"Arumugam P, Manicka Vasagam J, Jayaseelan VP. NKAP: A new m6A RNA binding protein predicts prognosis and immunotherapy response in head and neck squamous cell carcinoma. J Stomatol Oral Maxillofac Surg [Internet]. 2025;126.https:\/\/doi.org\/10.1016\/j.jormas.2025.102265","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"319_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102383","author":"H Fritah","year":"2022","unstructured":"Fritah H, Rovelli R, Chiang CLL, Kandalaft LE. The current clinical landscape of personalized cancer vaccines. Cancer Treat Rev. 2022.https:\/\/doi.org\/10.1016\/j.ctrv.2022.102383","journal-title":"Cancer Treat Rev"},{"key":"319_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111756","author":"K Marhelava","year":"2019","unstructured":"Marhelava K, Pilch Z, Bajor M, Graczyk-Jarzynka A, Zagozdzon R. Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer. Cancers (Basel). 2019.https:\/\/doi.org\/10.3390\/cancers11111756","journal-title":"Cancers (Basel)"},{"key":"319_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell. 2015.https:\/\/doi.org\/10.1016\/j.cell.2015.03.030","journal-title":"Cell"},{"key":"319_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.868695","author":"SK Kim","year":"2022","unstructured":"Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol. 2022.https:\/\/doi.org\/10.3389\/fphar.2022.868695","journal-title":"Front Pharmacol"},{"key":"319_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T-cell basic science to clinical practice. Nat Rev Immunol. 2020. https:\/\/doi.org\/10.1038\/s41577-020-0306-5","journal-title":"Nat Rev Immunol"},{"key":"319_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12834","author":"D Gardner","year":"2014","unstructured":"Gardner D, Jeffery LE, Sansom DM. Understanding the CD28\/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. American Journal of Transplantation. 2014.https:\/\/doi.org\/10.1111\/ajt.12834","journal-title":"Am J Transplant"},{"key":"319_CR32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1595","author":"EJ Lipson","year":"2011","unstructured":"Lipson EJ, Drake CG. Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clinical Cancer Research. 2011.https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1595","journal-title":"Clin Cancer Res"},{"key":"319_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.08.069","author":"J Gao","year":"2016","unstructured":"Lipson EJ, Drake CG. Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clinical Cancer Research. 2011. https:\/\/doi.org\/10.1016\/j.cell.2016.08.069","journal-title":"Cell"},{"key":"319_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000041","author":"P Du Rusquec","year":"2014","unstructured":"Du Rusquec P, Saint-Jean M, Brocard A, Peuvrel L, Khammari A, Qu\u00e9reux G, et al. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. Journal of Immunotherapy. 2014;37.https:\/\/doi.org\/10.1097\/CJI.0000000000000041","journal-title":"J Immunother"},{"key":"319_CR35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090331","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008.https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"key":"319_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6.https:\/\/doi.org\/10.1126\/sciadv.abd2712","journal-title":"Sci Adv"},{"key":"319_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade6256","author":"EA Philips","year":"2024","unstructured":"Philips EA, Liu J, Kvalvaag A, M\u00f8rch AM, Tocheva AS, Ng C, et al. Transmembrane domain\u2013driven PD-1 dimers mediate T-cell inhibition. Sci Immunol. 2024;9.https:\/\/doi.org\/10.1126\/sciimmunol.ade6256","journal-title":"Sci Immunol"},{"key":"319_CR38","doi-asserted-by":"crossref","unstructured":"Dang TO, Ogunniyi A, Barbee MS, Drilon A. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther. 2016;16.","DOI":"10.1586\/14737140.2016.1123626"},{"key":"319_CR39","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, et al. Five-year survival outcomes with Nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer in CheckMate 227. Journal of Clinical Oncology. 2023;41.","DOI":"10.1200\/JCO.22.01503"},{"key":"319_CR40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","author":"MD Hellmann","year":"2019","unstructured":"Philips EA, Liu J, Kvalvaag A, M\u00f8rch AM, Tocheva AS, Ng C, et al. Transmembrane domain\u2013driven PD-1 dimers mediate T-cell inhibition. Sci Immunol. 2024;9. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"key":"319_CR41","doi-asserted-by":"crossref","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019.","DOI":"10.1186\/s12943-019-1091-2"},{"key":"319_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12520","author":"M Das","year":"2017","unstructured":"Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017.https:\/\/doi.org\/10.1111\/imr.12520","journal-title":"Immunol Rev"},{"key":"319_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.04.011","author":"S Kandel","year":"2021","unstructured":"Kandel S, Adhikary P, Li G, Cheng K. The TIM3\/Gal9 signaling pathway: An emerging target for cancer immunotherapy. Cancer Lett. 2021. https:\/\/doi.org\/10.1016\/j.canlet.2021.04.011","journal-title":"Cancer Lett"},{"key":"319_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03516-1","author":"N Sauer","year":"2023","unstructured":"Sauer N, Janicka N, Szlasa W, Skinderowicz B, Ko\u0142odzi\u0144ska K, Dwernicka W, et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunology, Immunotherapy. 2023. https:\/\/doi.org\/10.1007\/s00262-023-03516-1","journal-title":"Cancer Immunol Immunother"},{"key":"319_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00999","author":"B Seliger","year":"2019","unstructured":"Seliger B. Combinatorial Approaches with Checkpoint Inhibitors to Enhance Anti-tumor Immunity. Front Immunol. 2019.https:\/\/doi.org\/10.3389\/fimmu.2019.00999","journal-title":"Front Immunol"},{"key":"319_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.956090","author":"JL Huo","year":"2022","unstructured":"Huo JL, Wang YT, Fu WJ, Lu N, Liu ZS. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022.https:\/\/doi.org\/10.3389\/fimmu.2022.956090","journal-title":"Front Immunol"},{"key":"319_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105282","author":"L Chocarro","year":"2021","unstructured":"Chocarro L, Blanco E, Zuazo M, Arasanz H, Bocanegra A, Fern\u00e1ndez-Rubio L, et al. Understanding lag-3 signaling. Int J Mol Sci. 2021.https:\/\/doi.org\/10.3390\/ijms22105282","journal-title":"Int J Mol Sci"},{"key":"319_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01569-z","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24.https:\/\/doi.org\/10.1038\/s41590-023-01569-z","journal-title":"Nat Immunol"},{"key":"319_CR49","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1736792","author":"N Gestermann","year":"2020","unstructured":"Gestermann N, Saugy D, Martignier C, Till\u00e9 L, Fuertes Marraco SA, Zettl M, et al. LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma\/T-cell cocultures. Oncoimmunology. 2020;9. https:\/\/doi.org\/10.1080\/2162402X.2020.1736792","journal-title":"Oncoimmunology"},{"key":"319_CR50","doi-asserted-by":"publisher","DOI":"10.18632\/genesandcancer.180","author":"L Long","year":"2018","unstructured":"Long L, Zhang X, Chen F, Pan Q, Phiphatwatchara P, Zeng Y, et al. The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9.https:\/\/doi.org\/10.18632\/genesandcancer.180","journal-title":"Genes Cancer"},{"key":"319_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179958","author":"N Sauer","year":"2022","unstructured":"Sauer N, Szlasa W, Jonderko L, O\u015bliz\u0142o M, Kunachowicz D, Kulbacka J, et al. LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors. Int J Mol Sci. 2022.https:\/\/doi.org\/10.3390\/ijms23179958","journal-title":"Int J Mol Sci"},{"key":"319_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","author":"T Maruhashi","year":"2020","unstructured":"Sauer N, Szlasa W, Jonderko L, O\u015bliz\u0142o M, Kunachowicz D, Kulbacka J, et al. LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors. Int J Mol Sci. 2022. https:\/\/doi.org\/10.1136\/jitc-2020-001014","journal-title":"J Immunother Cancer"},{"key":"319_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05961-3","author":"W Tang","year":"2023","unstructured":"Tang W, Chen J, Ji T, Cong X. TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death Dis. 2023.https:\/\/doi.org\/10.1038\/s41419-023-05961-3","journal-title":"Cell Death Dis"},{"key":"319_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030200","author":"J Yeo","year":"2021","unstructured":"Yeo J, Ko M, Lee DH, Park Y, Jin HS. Tigit\/cd226 axis regulates anti-tumor immunity. Pharmaceuticals. 2021. https:\/\/doi.org\/10.3390\/ph14030200","journal-title":"Pharmaceuticals"},{"key":"319_CR55","doi-asserted-by":"crossref","unstructured":"Rotte A, Sahasranaman S, Budha N. Targeting tigit for immunotherapy of cancer: Update on clinical development. Biomedicines. 2021;9.","DOI":"10.3390\/biomedicines9091277"},{"key":"319_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01800-3","author":"X Chu","year":"2023","unstructured":"Chu X, Tian W, Wang Z, Zhang J, Zhou R. Coinhibition of TIGIT and PD-1\/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials. Mol Cancer. 2023.https:\/\/doi.org\/10.1186\/s12943-023-01800-3","journal-title":"Mol Cancer"},{"key":"319_CR57","unstructured":"National Cancer Institute. CAR T cells: engineering patients\u2019 immune cells to treat their cancers. National Cancer Institute. 2022."},{"key":"319_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113675","author":"AA Bhat","year":"2025","unstructured":"Bhat AA, Altamimi ASA, Goyal A, Goyal K, Kaur I, Kumar S, et al. The role of CD95 in modulating CAR T-cell therapy: Challenges and therapeutic opportunities in oncology. Int Immunopharmacol [Internet]. 2025;144.https:\/\/doi.org\/10.1016\/j.intimp.2024.113675","journal-title":"Int Immunopharmacol"},{"key":"319_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115074","author":"HM Almohaimeed","year":"2025","unstructured":"Almohaimeed HM, Chowdhury A, Sarkar S, Almars AI, Tounsi WA, Singh A, et al. Advances in cancer immunotherapy: The role of super NK and super CAR-T cells. Int Immunopharmacol [Internet]. 2025;161.https:\/\/doi.org\/10.1016\/j.intimp.2025.115074","journal-title":"Int Immunopharmacol"},{"key":"319_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202049064","author":"A Globerson Levin","year":"2021","unstructured":"Globerson Levin A, Rivi\u00e8re I, Eshhar Z, Sadelain M. CAR T cells: Building on the CD19 paradigm. Eur J Immunol. 2021.https:\/\/doi.org\/10.1002\/eji.202049064","journal-title":"Eur J Immunol"},{"key":"319_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00431-0","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhou W, Yang J, Yang J, Wang W. Chimeric antigen receptor engineered natural killer cells for cancer therapy. Exp Hematol Oncol. 2023.https:\/\/doi.org\/10.1186\/s40164-023-00431-0","journal-title":"Exp Hematol Oncol"},{"key":"319_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00312","author":"RY Alhabbab","year":"2020","unstructured":"Alhabbab RY. Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells. Front Genet. 2020. https:\/\/doi.org\/10.3389\/fgene.2020.00312","journal-title":"Front Genet"},{"key":"319_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01938-8","author":"T Chen","year":"2024","unstructured":"Chen T, Deng J, Zhang Y, Liu B, Liu R, Zhu Y, et al. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments. Mol Cancer. 2024;23. https:\/\/doi.org\/10.1186\/s12943-024-01938-8","journal-title":"Mol Cancer"},{"key":"319_CR64","doi-asserted-by":"crossref","unstructured":"Duan Z, Lin Z, Zhou S. Universal CAR T cell: engineering of universal T cell, modular CAR system, and applications. 2021.","DOI":"10.23977\/misbp.2021036"},{"key":"319_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T-cell therapy: current limitations and potential strategies. Blood Cancer J. 2021.https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"key":"319_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1335424","author":"S Smirnov","year":"2024","unstructured":"Smirnov S, Mateikovich P, Samochernykh K, Shlyakhto E. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic. Front Immunol. 2024.https:\/\/doi.org\/10.3389\/fimmu.2024.1335424","journal-title":"Front Immunol"},{"key":"319_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283","author":"MR Benmebarek","year":"2019","unstructured":"Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019.https:\/\/doi.org\/10.3390\/ijms20061283","journal-title":"Int J Mol Sci"},{"key":"319_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell. 2020.https:\/\/doi.org\/10.1016\/j.ccell.2020.07.005","journal-title":"Cancer Cell"},{"key":"319_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocit.2016.08.001","author":"AJ Smith","year":"2016","unstructured":"Smith AJ, Oertle J, Warren D, Prato D. Chimeric antigen receptor (CAR) T-cell therapy for malignant cancers: Summary and perspective. Journal of Cellular Immunotherapy. 2016;2.https:\/\/doi.org\/10.1016\/j.jocit.2016.08.001","journal-title":"J Cell Immunother"},{"key":"319_CR70","doi-asserted-by":"crossref","unstructured":"Acuto O, Michel F. CD28-mediated costimulation: a quantitative support for TCR signaling. Nat Rev Immunol. 2003.","DOI":"10.1038\/nri1248"},{"key":"319_CR71","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.11.6123","author":"A Hombach","year":"2001","unstructured":"Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, et al. Tumor-Specific T-Cell Activation by Recombinant Immunoreceptors: CD3\u03b6 Signaling and CD28 Costimulation Are Simultaneously, Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28\/CD3\u03b6 Signaling Receptor Molecule. The Journal of Immunology. 2001;167. https:\/\/doi.org\/10.4049\/jimmunol.167.11.6123","journal-title":"J Immunol"},{"key":"319_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24. https:\/\/doi.org\/10.1038\/nm.4478","journal-title":"Nat Med"},{"key":"319_CR73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.6.2791","author":"HM Finney","year":"1998","unstructured":"Finney HM, Lawson ADG, Bebbington CR, Weir ANC. Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product. The Journal of Immunology. 1998;161.https:\/\/doi.org\/10.4049\/jimmunol.161.6.2791","journal-title":"J Immunol"},{"key":"319_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0325-1","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019.https:\/\/doi.org\/10.1038\/s41416-018-0325-1","journal-title":"Br J Cancer"},{"key":"319_CR75","doi-asserted-by":"crossref","unstructured":"Du S, Yan J, Xue Y, Zhong Y, Dong Y. Adoptive cell therapy for cancer treatment. Exploration. 2023;3.","DOI":"10.1002\/EXP.20210058"},{"key":"319_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.97","author":"AD Fesnak","year":"2016","unstructured":"Fesnak AD, June CH, Levine BL. Engineered T cells: The promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016. https:\/\/doi.org\/10.1038\/nrc.2016.97","journal-title":"Nat Rev Cancer"},{"key":"319_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3910","author":"AP Rapoport","year":"2015","unstructured":"Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21. https:\/\/doi.org\/10.1038\/nm.3910","journal-title":"Nat Med"},{"key":"319_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3565","author":"MH Kershaw","year":"2013","unstructured":"Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 2013.https:\/\/doi.org\/10.1038\/nrc3565","journal-title":"Nat Rev Cancer"},{"key":"319_CR79","doi-asserted-by":"publisher","DOI":"10.1177\/1533033819831068","author":"J Zhang","year":"2019","unstructured":"Zhang J, Wang L. The emerging world of TCR-T-cell trials against cancer: A systematic review. Technol Cancer Res Treat. 2019. https:\/\/doi.org\/10.1177\/1533033819831068","journal-title":"Technol Cancer Res Treat"},{"key":"319_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01014-w","author":"S Liu","year":"2021","unstructured":"Liu S, Galat V, Galat4 Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021https:\/\/doi.org\/10.1186\/s13045-020-01014-w","journal-title":"J Hematol Oncol"},{"key":"319_CR81","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21596","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70.https:\/\/doi.org\/10.3322\/caac.21596","journal-title":"CA Cancer J Clin"},{"key":"319_CR82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine. 2020;382. https:\/\/doi.org\/10.1056\/NEJMoa1910607","journal-title":"N Engl J Med"},{"key":"319_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03651-8","author":"M Casanova-Acebes","year":"2021","unstructured":"Casanova-Acebes M, Dalla E, Leader AM, LeBerichel J, Nikolic J, Morales BM, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature. 2021;595.https:\/\/doi.org\/10.1038\/s41586-021-03651-8","journal-title":"Nature"},{"key":"319_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108499","author":"S Moradinasab","year":"2022","unstructured":"Moradinasab S, Pourbagheri-Sigaroodi A, Ghaffari SH, Bashash D. Targeting macrophage-mediated tumor cell phagocytosis: An overview of phagocytosis checkpoints blockade, nanomedicine intervention, and engineered CAR-macrophage therapy. Int Immunopharmacol. 2022.https:\/\/doi.org\/10.1016\/j.intimp.2021.108499","journal-title":"Int Immunopharmacol"},{"key":"319_CR85","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.36688","author":"MA Morrissey","year":"2018","unstructured":"Morrissey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, et al. Chimeric antigen receptors that trigger phagocytosis. Elife. 2018;7. https:\/\/doi.org\/10.7554\/eLife.36688","journal-title":"Elife"},{"key":"319_CR86","doi-asserted-by":"crossref","unstructured":"Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022.","DOI":"10.1186\/s13045-022-01247-x"},{"key":"319_CR87","doi-asserted-by":"crossref","unstructured":"Grimmett E, Al-Share B, Alkassab MB, Zhou RW, Desai A, Rahim MMA, et al. Cancer vaccines: past, present and future; a review article. Discover Oncology. 2022.","DOI":"10.1007\/s12672-022-00491-4"},{"key":"319_CR88","doi-asserted-by":"crossref","unstructured":"Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol. 2004;2.","DOI":"10.1038\/nrmicro867"},{"key":"319_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121413","author":"S Kamolratanakul","year":"2021","unstructured":"Morrissey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, et al. Chimeric antigen receptors that trigger phagocytosis. Elife. 2018;7.https:\/\/doi.org\/10.3390\/vaccines9121413","journal-title":"Vaccines"},{"key":"319_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/v14050986","author":"GEM Rizzo","year":"2022","unstructured":"Rizzo GEM, Cabibbo G, Crax\u00ec A. Hepatitis B Virus-Associated Hepatocellular Carcinoma. Viruses. 2022.https:\/\/doi.org\/10.3390\/v14050986","journal-title":"Viruses"},{"key":"319_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00616-5","author":"M Ghanaat","year":"2021","unstructured":"Ghanaat M, Goradel NH, Arashkia A, Ebrahimi N, Ghorghanlu S, Malekshahi ZV, et al. Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer. Acta Pharmacol Sin. 2021. https:\/\/doi.org\/10.1038\/s41401-021-00616-5","journal-title":"Acta Pharmacol Sin"},{"key":"319_CR92","doi-asserted-by":"crossref","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023.","DOI":"10.1038\/s41392-023-01674-3"},{"key":"319_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030699","author":"V Kurilin","year":"2024","unstructured":"Kurilin V, Alshevskaya A, Sennikov S. Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases. Biomedicines. 2024.https:\/\/doi.org\/10.3390\/biomedicines12030699","journal-title":"Biomedicines"},{"key":"319_CR94","doi-asserted-by":"crossref","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T Immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine. 2010;363.","DOI":"10.1056\/NEJMoa1001294"},{"key":"319_CR95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3126","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS. PROVENGE (sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine. Clinical Cancer Research. 2011.https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3126","journal-title":"Clin Cancer Res"},{"key":"319_CR96","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9749363","author":"N Abd-Aziz","year":"2022","unstructured":"Abd-Aziz N, Poh CL. Development of Peptide-Based Vaccines for Cancer. J Oncol. 2022.https:\/\/doi.org\/10.1155\/2022\/9749363","journal-title":"J Oncol"},{"key":"319_CR97","unstructured":"Bubenik J. Dendritic cell-based cancer vaccines. Folia Biol (Praha). 1999."},{"key":"319_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.004","author":"K Palucka","year":"2013","unstructured":"Palucka K, Banchereau J. Dendritic-Cell-Based Therapeutic Cancer Vaccines. Immunity. 2013.https:\/\/doi.org\/10.1016\/j.immuni.2013.07.004","journal-title":"Immunity"},{"key":"319_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01335-5","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021.https:\/\/doi.org\/10.1186\/s12943-021-01335-5","journal-title":"Mol Cancer"},{"key":"319_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923647","author":"LJ Duan","year":"2022","unstructured":"Duan LJ, Wang Q, Zhang C, Yang DX, Zhang XY. Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy. Front Immunol. 2022.https:\/\/doi.org\/10.3389\/fimmu.2022.923647","journal-title":"Front Immunol"},{"key":"319_CR101","doi-asserted-by":"crossref","unstructured":"Deng Z, Tian Y, Song J, An G, Yang P. mRNA vaccines: the dawn of a new era of cancer immunotherapy. Front Immunol. 2022.","DOI":"10.3389\/fimmu.2022.887125"},{"key":"319_CR102","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.5b00570","author":"Q Hu","year":"2015","unstructured":"Hu Q, Wu M, Fang C, Cheng C, Zhao M, Fang W, et al. Engineering Nanoparticle-Coated Bacteria as Oral DNA Vaccines for Cancer Immunotherapy. Nano Lett. 2015;15. https:\/\/doi.org\/10.1021\/acs.nanolett.5b00570","journal-title":"Nano Lett"},{"key":"319_CR103","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.980686","author":"B Yang","year":"2014","unstructured":"Yang B, Jeang J, Yang A, Wu TC, Hung CF. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10. https:\/\/doi.org\/10.4161\/21645515.2014.980686","journal-title":"Hum Vaccin Immunother"},{"key":"319_CR104","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2018.0019","author":"KC Conlon","year":"2019","unstructured":"Conlon KC, Miljkovic MD, Waldmann TA. Cytokines in the Treatment of Cancer. Journal of Interferon and Cytokine Research. 2019;39. https:\/\/doi.org\/10.1089\/jir.2018.0019","journal-title":"J Interferon Cytokine Res"},{"key":"319_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.872010","author":"SA Atallah-Yunes","year":"2022","unstructured":"Atallah-Yunes SA, Robertson MJ. Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.872010","journal-title":"Front Immunol"},{"key":"319_CR106","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1163462","author":"T Jiang","year":"2016","unstructured":"Atallah-Yunes SA, Robertson MJ. Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives. Front Immunol. 2022.https:\/\/doi.org\/10.1080\/2162402x.2016.1163462","journal-title":"Oncoimmunology"},{"key":"319_CR107","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9056173","author":"H Choudhry","year":"2018","unstructured":"Choudhry H, Helmi N, Abdulaal WH, Zeyadi M, Zamzami MA, Wu W, et al. Prospects of IL-2 in Cancer Immunotherapy. Biomed Res Int. 2018. https:\/\/doi.org\/10.1155\/2018\/9056173","journal-title":"BioMed Res Int"},{"key":"319_CR108","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.33078","author":"J Kirkwood","year":"2002","unstructured":"Kirkwood J. Cancer immunotherapy: The interferon-\u03b1 experience. Semin Oncol. 2002;29.https:\/\/doi.org\/10.1053\/sonc.2002.33078","journal-title":"Semin Oncol"},{"key":"319_CR109","doi-asserted-by":"crossref","unstructured":"Aric\u00f2 E, Castiello L, Capone I, Gabriele L, Belardelli F. Type i interferons and cancer: An evolving story demanding novel clinical applications. Cancers (Basel). 2019;11.","DOI":"10.3390\/cancers11121943"},{"key":"319_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092116","author":"HM Lee","year":"2022","unstructured":"Lee HM, Lee HJ, Chang JE. Inflammatory Cytokine: An Attractive Target for Cancer Treatment. Biomedicines. 2022.https:\/\/doi.org\/10.3390\/biomedicines10092116","journal-title":"Biomedicines"},{"key":"319_CR111","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0015","author":"EA Chiocca","year":"2014","unstructured":"Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2.https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0015","journal-title":"Cancer Immunol Res"},{"key":"319_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2019.11.016","author":"E Yl\u00f6sm\u00e4ki","year":"2020","unstructured":"Yl\u00f6sm\u00e4ki E, Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy. Curr Opin Biotechnol. 2020.https:\/\/doi.org\/10.1016\/j.copbio.2019.11.016","journal-title":"Curr Opin Biotechnol"},{"key":"319_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1082797","author":"RK Omole","year":"2022","unstructured":"Omole RK, Oluwatola O, Akere MT, Eniafe J, Agboluaje EO, Daramola OB, et al. Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.1082797","journal-title":"Front Pharmacol"},{"key":"319_CR114","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02830-x","author":"C Tang","year":"2022","unstructured":"Tang C, Li L, Mo T, Na J, Qian Z, Fan D, et al. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical. Clinical and Translational Oncology. 2022.https:\/\/doi.org\/10.1007\/s12094-022-02830-x","journal-title":"Clin Transl Oncol"},{"key":"319_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/v13071271","author":"A Malogolovkin","year":"2021","unstructured":"Malogolovkin A, Gasanov N, Egorov A, Weener M, Ivanov R, Karabelsky A. Combinatorial approaches for cancer treatment using oncolytic viruses: Projecting the perspectives through clinical trials outcomes. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13071271","journal-title":"Viruses"},{"key":"319_CR116","doi-asserted-by":"crossref","unstructured":"Zolaly MA, Mahallawi W, Khawaji ZY, Alahmadi MA. The clinical advances of oncolytic viruses in cancer immunotherapy. Cureus. 2023;","DOI":"10.7759\/cureus.40742"},{"key":"319_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: A new class of immunotherapy drugs. Nat Rev Drug Discov. 2015.https:\/\/doi.org\/10.1038\/nrd4663","journal-title":"Nat Rev Drug Discov"},{"key":"319_CR118","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03404-6","author":"S Huang","year":"2020","unstructured":"Huang S, van Duijnhoven SMJ, Sijts AJAM, van Elsas A. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. J Cancer Res Clin Oncol. 2020.https:\/\/doi.org\/10.1007\/s00432-020-03404-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"319_CR119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3770","author":"B Blanco","year":"2021","unstructured":"Blanco B, Dom\u00ednguez-Alonso C, Alvarez-Vallina L. Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy. Clinical Cancer Research. 2021.https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3770","journal-title":"Clin Cancer Res"},{"key":"319_CR120","doi-asserted-by":"crossref","unstructured":"Zhang T, Lin Y, Gao Q. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biol Med. 2023.","DOI":"10.20892\/j.issn.2095-3941.2023.0002"},{"key":"319_CR121","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1161185","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Bargou R. Blinatumomab: A CD19\/CD3 bispecific T-cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma. 2016;57.https:\/\/doi.org\/10.3109\/10428194.2016.1161185","journal-title":"Leuk Lymphoma"},{"key":"319_CR122","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016243","author":"L Zhao","year":"2022","unstructured":"Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, et al. A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood. 2022;140. https:\/\/doi.org\/10.1182\/blood.2022016243","journal-title":"Blood"},{"key":"319_CR123","doi-asserted-by":"crossref","unstructured":"Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, et al. Bispecific antibodies: from research to clinical application. Front Immunol. 2021.","DOI":"10.3389\/fimmu.2021.626616"},{"key":"319_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1291836","author":"X Guo","year":"2023","unstructured":"Guo X, Wu Y, Xue Y, Xie N, Shen G. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1291836","journal-title":"Front Immunol"},{"key":"319_CR125","doi-asserted-by":"publisher","DOI":"10.48022\/mbl.2307.07014","author":"YH Choi","year":"2023","unstructured":"Choi YH, Song HS, Lee SK, Song CH, Kim JH, Han KH. Advancements in Bispecific Antibody Development and Research Trends. Microbiology and Biotechnology Letters. 2023.https:\/\/doi.org\/10.48022\/mbl.2307.07014","journal-title":"Microbiol Biotechnol Lett"},{"key":"319_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020504","author":"P Muthukutty","year":"2023","unstructured":"Muthukutty P, Woo HY, Ragothaman M, Yoo SY. Recent Advances in Cancer Immunotherapy Delivery Modalities. Pharmaceutics. 2023.https:\/\/doi.org\/10.3390\/pharmaceutics15020504","journal-title":"Pharmaceutics"},{"key":"319_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602526","author":"A Roth","year":"2005","unstructured":"Roth A, Rohrbach F, Weth R, Frisch B, Schuber F, Wels WS. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2\/HER2 peptide-based vaccination construct. Br J Cancer. 2005;92.https:\/\/doi.org\/10.1038\/sj.bjc.6602526","journal-title":"Br J Cancer"},{"key":"319_CR128","doi-asserted-by":"crossref","unstructured":"Yuba E, Harada A, Sakanishi Y, Watarai S, Kono K. A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy. Biomaterials. 2013;34.","DOI":"10.1016\/j.biomaterials.2012.12.031"},{"key":"319_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.05.037","author":"Y Zheng","year":"2013","unstructured":"Zheng Y, Stephan MT, Gai SA, Abraham W, Shearer A, Irvine DJ. In vivo targeting of adoptively transferred T cells with antibody- and cytokine-conjugated liposomes. Journal of Controlled Release. 2013;172.https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.037","journal-title":"J Control Release"},{"key":"319_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14717-x","author":"K Aoyama","year":"2017","unstructured":"Aoyama K, Kuroda S, Morihiro T, Kanaya N, Kubota T, Kakiuchi Y, et al. Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system. Sci Rep. 2017;7.https:\/\/doi.org\/10.1038\/s41598-017-14717-x","journal-title":"Sci Rep"},{"key":"319_CR131","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.8b09348","author":"J Liu","year":"2018","unstructured":"Liu J, Liu X, Han Y, Zhang J, Liu D, Ma G, et al. Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses. ACS Appl Mater Interfaces. 2018;10.https:\/\/doi.org\/10.1021\/acsami.8b09348","journal-title":"ACS Appl Mater Interfaces"},{"key":"319_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31926-9","author":"M Reda","year":"2022","unstructured":"Reda M, Ngamcherdtrakul W, Nelson MA, Siriwon N, Wang R, Zaidan HY, et al. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nat Commun. 2022;13.https:\/\/doi.org\/10.1038\/s41467-022-31926-9","journal-title":"Nat Commun"},{"key":"319_CR133","doi-asserted-by":"crossref","unstructured":"Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, et al. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2022;280.","DOI":"10.1016\/j.biomaterials.2021.121312"},{"key":"319_CR134","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax5032","author":"KW Huang","year":"2020","unstructured":"Huang KW, Hsu FF, Qiu JT, Chern GJ, Lee YA, Chang CC, et al. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Sci Adv. 2020;6.https:\/\/doi.org\/10.1126\/sciadv.aax5032","journal-title":"Sci Adv"},{"key":"319_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.03.135","author":"DG Roy","year":"2020","unstructured":"Roy DG, Bell JC, Bourgeois-Daigneault MC. Magnetic targeting of oncolytic VSV-based therapies improves infection of tumor cells in the presence of virus-specific neutralizing antibodies in vitro. Biochem Biophys Res Commun. 2020;526.https:\/\/doi.org\/10.1016\/j.bbrc.2020.03.135","journal-title":"Biochem Biophys Res Commun"},{"key":"319_CR136","doi-asserted-by":"publisher","DOI":"10.1021\/mp100123t","author":"N Tresilwised","year":"2010","unstructured":"Tresilwised N, Pithayanukul P, Mykhaylyk O, Holm PS, Holzm\u00fcller R, Anton M, et al. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force. Mol Pharm. 2010;7.https:\/\/doi.org\/10.1021\/mp100123t","journal-title":"Mol Pharm"},{"key":"319_CR137","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.0c05039","author":"Y Yin","year":"2021","unstructured":"Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R, et al. In Situ Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy. Nano Lett. 2021;21.https:\/\/doi.org\/10.1021\/acs.nanolett.0c05039","journal-title":"Nano Lett"},{"key":"319_CR138","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201506312","author":"C Wang","year":"2016","unstructured":"Wang C, Sun W, Wright G, Wang AZ, Gu Z. Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody. Advanced Materials. 2016;28. https:\/\/doi.org\/10.1002\/adma.201506312","journal-title":"Adv Mater"},{"key":"319_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-020-0793-6","author":"S Liu","year":"2021","unstructured":"Liu S, Jiang Q, Zhao X, Zhao R, Wang Y, Wang Y, et al. A DNA nanodevice-based vaccine for cancer immunotherapy. Nat Mater. 2021;20.https:\/\/doi.org\/10.1038\/s41563-020-0793-6","journal-title":"Nat Mater"},{"key":"319_CR140","doi-asserted-by":"crossref","unstructured":"Ni Q, Zhang F, Liu Y, Wang Z, Yu G, Liang B, et al. A biadjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci Adv. 2020;6.","DOI":"10.1126\/sciadv.aaw6071"},{"key":"319_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202000083","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Shen T, Zhou S, Wang W, Lin S, Zhu G. pH-Responsive STING-Activating DNA Nanovaccines for Cancer Immunotherapy. Adv Ther (Weinh). 2020;3. https:\/\/doi.org\/10.1002\/adtp.202000083","journal-title":"Adv Ther"},{"key":"319_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108298","author":"NH Goradel","year":"2021","unstructured":"Goradel NH, Negahdari B, Mohajel N, Malekshahi ZV, Shirazi MMA, Arashkia A. Heterologous administration of HPV16 E7 epitope-loaded nanocomplexes inhibits tumor growth in mouse model. Int Immunopharmacol. 2021;101.https:\/\/doi.org\/10.1016\/j.intimp.2021.108298","journal-title":"Int Immunopharmacol"},{"key":"319_CR143","doi-asserted-by":"crossref","unstructured":"Wang Y, Chen X, Tian B, Liu J, Yang L, Zeng L, et al. Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer. Theranostics. 2017;7.","DOI":"10.7150\/thno.16532"},{"key":"319_CR144","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2017.1265291","author":"ZQ Yuan","year":"2017","unstructured":"Yuan ZQ, Kolluri KK, Gowers KHC, Janes SM. TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy. J Extracell Vesicles. 2017;6. https:\/\/doi.org\/10.1080\/20013078.2017.1265291","journal-title":"J Extracell Vesicles"},{"key":"319_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.53","author":"J Ma","year":"2016","unstructured":"Ma J, Zhang Y, Tang K, Zhang H, Yin X, Li Y, et al. Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles. Cell Res. 2016;26. https:\/\/doi.org\/10.1038\/cr.2016.53","journal-title":"Cell Res"},{"key":"319_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2016.09.031","author":"M Morishita","year":"2016","unstructured":"Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y. Exosome-based tumor antigens\u2013adjuvant codelivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials. 2016;111.https:\/\/doi.org\/10.1016\/j.biomaterials.2016.09.031","journal-title":"Biomaterials"},{"key":"319_CR147","doi-asserted-by":"crossref","unstructured":"Liang Q, Bie N, Yong T, Tang K, Shi X, Wei Z, et al. The softness of tumor-cell-derived microparticles regulates their drug-delivery efficiency. Nat Biomed Eng. 2019;3.","DOI":"10.1038\/s41551-019-0405-4"},{"key":"319_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.180","author":"SI Ohno","year":"2013","unstructured":"Ohno SI, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microrna to breast cancer cells. Molecular Therapy. 2013;21.https:\/\/doi.org\/10.1038\/mt.2012.180","journal-title":"Mol Ther"},{"key":"319_CR149","doi-asserted-by":"crossref","unstructured":"Kooijmans SAA, Aleza CG, Roffler SR, van Solinge WW, Vader P, Schiffelers RM. Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumor cell targeting. J Extracell Vesicles. 2016;5.","DOI":"10.3402\/jev.v5.31053"},{"key":"319_CR150","doi-asserted-by":"crossref","unstructured":"Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J, et al. Delivery of chemotherapeutic drugs in tumor cell-derived microparticles. Nat Commun. 2012;3.","DOI":"10.1038\/ncomms2282"},{"key":"319_CR151","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201706719","author":"H Phuengkham","year":"2018","unstructured":"Phuengkham H, Song C, Um SH, Lim YT. Implantable Synthetic Immune Niche for Spatiotemporal Modulation of Tumor-Derived Immunosuppression and Systemic Antitumor Immunity: Postoperative Immunotherapy. Advanced Materials. 2018;30. https:\/\/doi.org\/10.1002\/adma.201706719","journal-title":"Adv Mater"},{"key":"319_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/nmat2357","author":"OA Ali","year":"2009","unstructured":"Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ. Infection-mimicking materials to program dendritic cells in situ. Nat Mater. 2009;8.https:\/\/doi.org\/10.1038\/nmat2357","journal-title":"Nat Mater"},{"key":"319_CR153","doi-asserted-by":"crossref","unstructured":"Ahn YH, Ren L, Kim SM, Seo SH, Jung CR, Kim DS, et al. A three-dimensional hyaluronic acid-based niche enhances the therapeutic efficacy of human natural killer cell-based cancer immunotherapy. Biomaterials. 2020;247.","DOI":"10.1016\/j.biomaterials.2020.119960"},{"key":"319_CR154","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1074374","author":"Y Li","year":"2016","unstructured":"Li Y, Fang M, Zhang J, Wang J, Song Y, Shi J, et al. Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology. 2016;5.https:\/\/doi.org\/10.1080\/2162402X.2015.1074374","journal-title":"Oncoimmunology"},{"key":"319_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2018.01.004","author":"H Song","year":"2018","unstructured":"Song H, Huang P, Niu J, Shi G, Zhang C, Kong D, et al. Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma. Biomaterials. 2018;159.https:\/\/doi.org\/10.1016\/j.biomaterials.2018.01.004","journal-title":"Biomaterials"},{"key":"319_CR156","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3682","author":"C Wang","year":"2018","unstructured":"Wang C, Wang J, Zhang X, Yu S, Wen D, Hu Q, et al. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci Transl Med. 2018;10.https:\/\/doi.org\/10.1126\/scitranslmed.aan3682","journal-title":"Sci Transl Med"},{"key":"319_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11090429","author":"X Xie","year":"2019","unstructured":"Xie X, Wang H, Williams GR, Yang Y, Zheng Y, Wu J, et al. Erythrocyte membrane cloaked curcumin-loaded nanoparticles for enhanced chemotherapy. Pharmaceutics. 2019;11.https:\/\/doi.org\/10.3390\/pharmaceutics11090429","journal-title":"Pharmaceutics"},{"key":"319_CR158","doi-asserted-by":"crossref","unstructured":"Zhang L, Wang Z, Zhang Y, Cao F, Dong K, Ren J, et al. Erythrocyte membrane cloaked metal-organic framework nanoparticle as biomimetic nanoreactor for starvation-activated colon cancer therapy. ACS Nano. 2018;12.","DOI":"10.1021\/acsnano.8b05200"},{"key":"319_CR159","doi-asserted-by":"crossref","unstructured":"Luk BT, Fang RH, Hu CMJ, Copp JA, Thamphiwatana S, Dehaini D, et al. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics. 2016;6.","DOI":"10.7150\/thno.14471"},{"key":"319_CR160","doi-asserted-by":"crossref","unstructured":"Zhang L, Li R, Chen H, Wei J, Qian H, Su S, et al. Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer. Int J Nanomedicine. 2017;12.","DOI":"10.2147\/IJN.S126016"},{"key":"319_CR161","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b05292","author":"G Deng","year":"2018","unstructured":"Deng G, Sun Z, Li S, Peng X, Li W, Zhou L, et al. Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth. ACS Nano. 2018;12.https:\/\/doi.org\/10.1021\/acsnano.8b05292","journal-title":"ACS Nano"},{"key":"319_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9070092","author":"P Sridhar","year":"2017","unstructured":"Sridhar P, Petrocca F. Regional delivery of chimeric antigen receptor (CAR) T cells for cancer therapy. Cancers (Basel). 2017.https:\/\/doi.org\/10.3390\/cancers9070092","journal-title":"Cancers (Basel)"},{"key":"319_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01096-0","author":"Z Cheng","year":"2021","unstructured":"Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021.https:\/\/doi.org\/10.1186\/s13045-021-01096-0","journal-title":"J Hematol Oncol"},{"key":"319_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01605-4","author":"S Waheed","year":"2022","unstructured":"Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J. Engineering nanodrug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnology. 2022. https:\/\/doi.org\/10.1186\/s12951-022-01605-4","journal-title":"J Nanobiotechnol"},{"key":"319_CR165","doi-asserted-by":"publisher","DOI":"10.1039\/D0TB00649A","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Chen X, Cao J, Gao H. Overcoming the biological barriers in the tumor microenvironment for improving drug delivery and efficacy. J Mater Chem B. 2020.https:\/\/doi.org\/10.1039\/D0TB00649A","journal-title":"J Mater Chem B"},{"key":"319_CR166","doi-asserted-by":"crossref","unstructured":"Hosseini M, Haji-Fatahaliha M, Jadidi-Niaragh F, Majidi J, Yousefi M. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artif Cells Nanomed Biotechnol. 2016;44.","DOI":"10.3109\/21691401.2014.998830"},{"key":"319_CR167","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00193","author":"Y Yao","year":"2020","unstructured":"Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci. 2020. https:\/\/doi.org\/10.3389\/fmolb.2020.00193","journal-title":"Front Mol Biosci"},{"key":"319_CR168","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.9b08142","author":"YH Cheng","year":"2020","unstructured":"Cheng YH, He C, Riviere JE, Monteiro-Riviere NA, Lin Z. Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach. ACS Nano. 2020;14. https:\/\/doi.org\/10.1021\/acsnano.9b08142","journal-title":"ACS Nano"},{"key":"319_CR169","doi-asserted-by":"publisher","DOI":"10.1515\/biol-2018-0035","author":"A Pudlarz","year":"2018","unstructured":"Pudlarz A, Szemraj J. Nanoparticles as carriers of proteins, peptides and other therapeutic molecules. Open Life Sci. 2018.https:\/\/doi.org\/10.1515\/biol-2018-0035","journal-title":"Open Life Sci"},{"key":"319_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2022.102915","author":"VR Shinde","year":"2022","unstructured":"Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles. Photodiagnosis Photodyn Ther. 2022. https:\/\/doi.org\/10.1016\/j.pdpdt.2022.102915","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"319_CR171","doi-asserted-by":"crossref","unstructured":"Wang H, Li Z, Lu S, Li C, Zhao W, Zhao Y, et al. Nano micelles of cellulose-graft-poly (L-lactic acid) anchored with epithelial cell adhesion antibody for enhanced drug loading and anti-tumor effect. Mater Today, Commun. 2020;22.","DOI":"10.1016\/j.mtcomm.2019.100764"},{"key":"319_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.10.020","author":"N Badrinath","year":"2018","unstructured":"Badrinath N, Jeong Y Il, Woo HY, Bang SY, Kim C, Heo J, et al. Local delivery of a cancer-favoring oncolytic vaccinia virus via poly (lactic-co-glycolic acid) nanofiber for theranostic purposes. Int J Pharm. 2018;552. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.10.020","journal-title":"Int J Pharm"},{"key":"319_CR173","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-018-0146-7","author":"CS Chiang","year":"2018","unstructured":"Chiang CS, Lin YJ, Lee R, Lai YH, Cheng HW, Hsieh CH, et al. Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumor-localized immunotherapy. Nat Nanotechnol. 2018;13. https:\/\/doi.org\/10.1038\/s41565-018-0146-7","journal-title":"Nat Nanotechnol"},{"key":"319_CR174","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111867","author":"A Mohapatra","year":"2021","unstructured":"Mohapatra A, Sathiyamoorthy P, Park IK. Metallic nanoparticle-mediated immune cell regulation and advanced cancer immunotherapy. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13111867","journal-title":"Pharmaceutics"},{"key":"319_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-020-00781-4","author":"J Xu","year":"2020","unstructured":"Xu J, Lv J, Zhuang Q, Yang Z, Cao Z, Xu L, et al. A general strategy toward personalized nanovaccines based on fluoropolymers for postsurgical cancer immunotherapy. Nat Nanotechnol. 2020;15. https:\/\/doi.org\/10.1038\/s41565-020-00781-4","journal-title":"Nat Nanotechnol"},{"key":"319_CR176","doi-asserted-by":"crossref","unstructured":"Luo Z, He T, Liu P, Yi Z, Zhu S, Liang X, et al. Self-adjuvanted molecular activator (SeaMac) nanovaccines promote cancer immunotherapy. Adv Healthc Mater. 2021;10.","DOI":"10.1002\/adhm.202002080"},{"key":"319_CR177","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S239751","author":"J Wang","year":"2020","unstructured":"Wang J, Wu X, Shen P, Wang J, Shen Y, Shen Y, et al. Applications of inorganic nanomaterials in photothermal therapy based on combinational cancer treatment. Int J Nanomedicine. 2020. https:\/\/doi.org\/10.2147\/IJN.S239751","journal-title":"Int J Nanomedicine"},{"key":"319_CR178","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27596","author":"H Montaseri","year":"2020","unstructured":"Montaseri H, Kruger CA, Abrahamse H. Review: Organic nanoparticle based active targeting for photodynamic therapy treatment of breast cancer cells. Oncotarget. 2020. https:\/\/doi.org\/10.18632\/oncotarget.27596","journal-title":"Oncotarget"},{"key":"319_CR179","doi-asserted-by":"publisher","DOI":"10.1186\/s40580-019-0216-z","author":"J Kim","year":"2020","unstructured":"Kim J, Chun SH, Amornkitbamrung L, Song C, Yuk JS, Ahn SY, et al. Gold nanoparticle clusters for the investigation of therapeutic efficiency against prostate cancer under near-infrared irradiation. Nano Converg. 2020;7.https:\/\/doi.org\/10.1186\/s40580-019-0216-z","journal-title":"Nano Convergence"},{"key":"319_CR180","doi-asserted-by":"crossref","unstructured":"Lu Z, Bai S, Jiang Y, Wu S, Xu D, Zhang J, et al. Amplifying dendritic cell activation by bioinspired nanometal organic frameworks for synergistic sonoimmunotherapy. Small. 2022;18.","DOI":"10.1002\/smll.202203952"},{"key":"319_CR181","doi-asserted-by":"publisher","DOI":"10.7150\/thno.38425","author":"S Lim","year":"2019","unstructured":"Lim S, Park J, Shim MK, Um W, Yoon HY, Ryu JH, et al. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics. 2019. https:\/\/doi.org\/10.7150\/thno.38425","journal-title":"Theranostics"},{"key":"319_CR182","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.8","author":"L Cai","year":"2020","unstructured":"Cai L, Xu J, Yang Z, Tong R, Dong Z, Wang C, et al. Engineered biomaterials for cancer immunotherapy. MedComm (Beijing). 2020.https:\/\/doi.org\/10.1002\/mco2.8","journal-title":"MedComm"},{"key":"319_CR183","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201804490","author":"L Ren","year":"2018","unstructured":"Ren L, Lim YT. Degradation-Regulatable Architectured Implantable Macroporous Scaffold for the Spatiotemporal Modulation of Immunosuppressive Microenvironment and Enhanced Combination Cancer Immunotherapy. Adv Funct Mater. 2018;28.https:\/\/doi.org\/10.1002\/adfm.201804490","journal-title":"Adv Funct Mater"},{"key":"319_CR184","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.612950","author":"J Li","year":"2020","unstructured":"Li J, Luo Y, Li B, Xia Y, Wang H, Fu C. Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy. Front Bioeng Biotechnol. 2020. https:\/\/doi.org\/10.3389\/fbioe.2020.612950","journal-title":"Front Bioeng Biotechnol"},{"key":"319_CR185","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.630943","author":"MH Cai","year":"2021","unstructured":"Cai MH, Chen XY, Fu LQ, Du WL, Yang X, Mou XZ, et al. Design and Development of Hybrid Hydrogels for Biomedical Applications: Recent Trends in Anticancer Drug Delivery and Tissue Engineering. Front Bioeng Biotechnol. 2021. https:\/\/doi.org\/10.3389\/fbioe.2021.630943","journal-title":"Front Bioeng Biotechnol"},{"key":"319_CR186","doi-asserted-by":"crossref","unstructured":"Liu M, Cao Z, Zhang R, Chen Y, Yang X. Injectable supramolecular hydrogel for locoregional immune checkpoint blockade and enhanced cancer chemo-immunotherapy. ACS Appl Mater Interfaces. 2021;13.","DOI":"10.1021\/acsami.1c08285"},{"key":"319_CR187","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6977","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science (1979). 2020.https:\/\/doi.org\/10.1126\/science.aau6977","journal-title":"Science"},{"key":"319_CR188","doi-asserted-by":"publisher","DOI":"10.1039\/D0BM01385D","author":"S Li","year":"2020","unstructured":"Li S, Xu J, Qian J, Gao X. Engineering extracellular vesicles for cancer therapy: Recent advances and challenges in clinical translation. Biomater Sci. 2020.https:\/\/doi.org\/10.1039\/D0BM01385D","journal-title":"Biomater Sci"},{"key":"319_CR189","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010122","author":"RO Elliott","year":"2021","unstructured":"Elliott RO, He M. Unlocking the power of exosomes for crossing biological barriers in drug delivery. Pharmaceutics. 2021.https:\/\/doi.org\/10.3390\/pharmaceutics13010122","journal-title":"Pharmaceutics"},{"key":"319_CR190","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.7b06464","author":"J Wang","year":"2017","unstructured":"Wang J, Li W, Zhang L, Ban L, Chen P, Du W, et al. Chemically Edited Exosomes with Dual Ligand Purified by Microfluidic Device for Active Targeted Drug Delivery to Tumor Cells. ACS Appl Mater Interfaces. 2017;9.https:\/\/doi.org\/10.1021\/acsami.7b06464","journal-title":"ACS Appl Mater Interfaces"},{"key":"319_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/nm0598-594","author":"L Zitvogel","year":"1998","unstructured":"Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med. 1998;4. https:\/\/doi.org\/10.1038\/nm0598-594","journal-title":"Nat Med"},{"key":"319_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2018.06.029","author":"G Jia","year":"2018","unstructured":"Jia G, Han Y, An Y, Ding Y, He C, Wang X, et al. NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo Biomaterials https:\/\/doi.org\/10.1016\/j.biomaterials.2018.06.029","journal-title":"Biomaterials"},{"key":"319_CR193","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0084","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, et al. Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy. Blood Cancer Discov. 2021. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0084","journal-title":"Blood Cancer Discov"},{"key":"319_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.794183","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yan X, Zhang F, Zhang X, Tang F, Han Z, et al. TCR-T Immunotherapy: The Challenges and Solutions. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2021.794183","journal-title":"Front Oncol"},{"key":"319_CR195","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-018-0235-9","author":"L Labanieh","year":"2018","unstructured":"Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2018.https:\/\/doi.org\/10.1038\/s41551-018-0235-9","journal-title":"Nat Biomed Eng"},{"key":"319_CR196","doi-asserted-by":"publisher","unstructured":"Grosskopf AK, Labanieh L, Klysz DD, Roth GA, Xu P, Adebowale O, et al. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Sci Adv. 2022;8.https:\/\/doi.org\/10.1126\/sciadv.abn8264","DOI":"10.1126\/sciadv.abn8264"},{"key":"319_CR197","doi-asserted-by":"crossref","unstructured":"Hu Q, Li H, Archibong E, Chen Q, Ruan H, Ahn S, et al. Inhibition of postsurgery tumor recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat Biomed Eng. 2021;5.","DOI":"10.1038\/s41551-021-00712-1"},{"key":"319_CR198","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3104","author":"SB Stephan","year":"2015","unstructured":"Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2015;33.https:\/\/doi.org\/10.1038\/nbt.3104","journal-title":"Nat Biotechnol"},{"key":"319_CR199","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01617","author":"H Sadozai","year":"2017","unstructured":"Sadozai H, Gruber T, Hunger RE, Schenk M. Recent successes and future directions in immunotherapy of cutaneous melanoma. Front Immunol. 2017.https:\/\/doi.org\/10.3389\/fimmu.2017.01617","journal-title":"Front Immunol"},{"key":"319_CR200","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014567469","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: Latest evidence and clinical potential. Ther Adv Med Oncol. 2015.https:\/\/doi.org\/10.1177\/1758834014567469","journal-title":"Ther Adv Med Oncol"},{"key":"319_CR201","doi-asserted-by":"publisher","DOI":"10.3390\/cells11203280","author":"N Krzy\u017canowska","year":"2022","unstructured":"Krzy\u017canowska N, Krawczyk P, Wojas-Krawczyk K, Kucharczyk T, Milanowski J. Immunotherapy in Non-Small Cell Lung Cancer Patients with Driver Alterations: A New Strategy? Cells. 2022. https:\/\/doi.org\/10.3390\/cells11203280","journal-title":"Cells"},{"key":"319_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2021.08.009","author":"X Ren","year":"2022","unstructured":"Ren X, Li Y, Nishimura C, Zang X. Crosstalk between the B7\/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. Genes Dis. 2022. https:\/\/doi.org\/10.1016\/j.gendis.2021.08.009","journal-title":"Genes Dis"},{"key":"319_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188447","author":"DY Lizardo","year":"2020","unstructured":"Lizardo DY, Kuang C, Hao S, Yu J, Huang Y, Zhang L. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochim Biophys Acta Rev Cancer. 2020. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188447","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"319_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019.https:\/\/doi.org\/10.1038\/s41575-019-0126-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"319_CR205","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2022.5385","author":"X Zhang","year":"2022","unstructured":"Zhang X, Ge X, Jiang T, Yang R, Li S. Research progress on immunotherapy in triple negative breast cancer (Review). Int J Oncol. 2022.https:\/\/doi.org\/10.3892\/ijo.2022.5385","journal-title":"Int J Oncol"},{"key":"319_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.10.042","author":"X Wang","year":"2019","unstructured":"Wang X, Qi Y, Kong X, Zhai J, Li Y, Song Y, et al. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment. Cancer Lett. 2019.https:\/\/doi.org\/10.1016\/j.canlet.2018.10.042","journal-title":"Cancer Lett"},{"key":"319_CR207","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30060432","author":"FM Maselli","year":"2023","unstructured":"Maselli FM, Giuliani F, Laface C, Perrone M, Melaccio A, De Santis P, et al. Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives. Current Oncology. 2023. https:\/\/doi.org\/10.3390\/curroncol30060432","journal-title":"Curr Oncol"},{"key":"319_CR208","doi-asserted-by":"crossref","unstructured":"Mendoza AA, Martin FV, Avalos JA, Valls TJO, Jimenez HMV, Perea EB. Advancements in glioblastoma management: a comprehensive review of therapeutic strategies and future directions. International Journal of Medical Science and Clinical Research Studies. 2023;03.","DOI":"10.47191\/ijmscrs\/v3-i10-74"},{"key":"319_CR209","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.311","author":"GE Konecny","year":"2016","unstructured":"Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: Current practice and future directions. Br J Cancer. 2016. https:\/\/doi.org\/10.1038\/bjc.2016.311","journal-title":"Br J Cancer"},{"key":"319_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30406-5","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016.https:\/\/doi.org\/10.1016\/S1470-2045(16)30406-5","journal-title":"Lancet Oncol"},{"key":"319_CR211","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01057-7","author":"L Incorvaia","year":"2019","unstructured":"Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, et al. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Adv Ther. 2019.https:\/\/doi.org\/10.1007\/s12325-019-01057-7","journal-title":"Adv Ther"},{"key":"319_CR212","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153997","author":"R Barroso-Sousa","year":"2023","unstructured":"Barroso-Sousa R, Pac\u00edfico JP, Sammons S, Tolaney SM. Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15153997","journal-title":"Cancers (Basel)"},{"key":"319_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.06.001","author":"S Maleki Vareki","year":"2017","unstructured":"Maleki Vareki S, Garrig\u00f3s C, Duran I. Biomarkers of response to PD-1\/PD-L1 inhibition. Crit Rev Oncol Hematol. 2017.https:\/\/doi.org\/10.1016\/j.critrevonc.2017.06.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"319_CR214","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2020.03.09","author":"J Remon","year":"2020","unstructured":"Remon J, Collazo A, Jimenez B. CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer. Transl Cancer Res. 2020.https:\/\/doi.org\/10.21037\/tcr.2020.03.09","journal-title":"Transl Cancer Res"},{"key":"319_CR215","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10120-024-01523-4","volume":"27","author":"A Ooki","year":"2024","unstructured":"Ooki A, Osumi H, Yoshino K, Yamaguchi K. 2024 Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair Gastric Cancer. 2024;27:907\u201331https:\/\/doi.org\/10.1007\/s10120-024-01523-4","journal-title":"Gastric Cancer"},{"key":"319_CR216","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9579","author":"JM Versluis","year":"2021","unstructured":"Versluis JM, Blankenstein S, Dimitriadis P, Sanders J, Hoefakker W, Broeks A, et al. The prognostic value of the interferon-gamma (IFN\u03b3) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy J Clin Oncol https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9579","journal-title":"J Clin Oncol"},{"key":"319_CR217","doi-asserted-by":"crossref","unstructured":"Porciello N, Franzese O, D\u2019Ambrosio L, Palermo B, Nistic\u00f2 P. T-cell repertoire diversity: friend or foe for protective antitumor response? Journal of Experimental and Clinical Cancer Research. 2022.","DOI":"10.1186\/s13046-022-02566-0"},{"key":"319_CR218","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01989","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study. Journal of Clinical Oncology. 2023;41.https:\/\/doi.org\/10.1200\/jco.22.01989","journal-title":"J Clin Oncol"},{"key":"319_CR219","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab004","author":"LA Emens","year":"2021","unstructured":"Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Di\u00e9ras V, et al. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021;113.https:\/\/doi.org\/10.1093\/jnci\/djab004","journal-title":"J Natl Cancer Inst"},{"key":"319_CR220","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01601","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. Journal of Clinical Oncology. 2024;42. https:\/\/doi.org\/10.1200\/JCO.23.01601","journal-title":"J Clin Oncol"},{"key":"319_CR221","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, et al. Avelumab\u00a0+ axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. Annals of Oncology [Internet]. 2025;36:387\u201392. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0923753424049871","DOI":"10.1016\/j.annonc.2024.12.008"},{"key":"319_CR222","unstructured":"Motzer RJ, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. Journal of Clinical Oncology. 2024;42."},{"key":"319_CR223","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004226","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Robert C, Brase JC, Gusenleitner D, Gasal E, Garrett J, et al. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). J Immunother Cancer. 2022;10.https:\/\/doi.org\/10.1136\/jitc-2021-004226","journal-title":"J Immunother Cancer"},{"key":"319_CR224","doi-asserted-by":"crossref","unstructured":"Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, et al. IMbrave150: efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in patients with barcelona clinic liver cancer stage b unresectable hepatocellular carcinoma: an exploratory analysis of the phase III study. Liver Cancer. 2023;12.","DOI":"10.1159\/000529996"},{"key":"319_CR225","doi-asserted-by":"crossref","unstructured":"Theelen WSME, Peulen HMU, Lalezari F, Van Der Noort V, De Vries JF, Aerts JGJV, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5.","DOI":"10.1001\/jamaoncol.2019.1478"},{"key":"319_CR226","doi-asserted-by":"crossref","unstructured":"Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase i\/ii study. Annals of Oncology. 2013;24.","DOI":"10.1093\/annonc\/mdt107"},{"key":"319_CR227","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01655-5","author":"L Derosa","year":"2022","unstructured":"Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small cell lung cancer. Nat Med. 2022;28.https:\/\/doi.org\/10.1038\/s41591-021-01655-5","journal-title":"Nat Med"},{"key":"319_CR228","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10457-y","author":"JSW Borgers","year":"2022","unstructured":"Borgers JSW, Burgers FH, Terveer EM, van Leerdam ME, Korse CM, Kessels R, et al. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib\/IIa trial. BMC Cancer. 2022;22.https:\/\/doi.org\/10.1186\/s12885-022-10457-y","journal-title":"BMC Cancer"},{"key":"319_CR229","doi-asserted-by":"crossref","unstructured":"Li Q, Li Y, Wang Y, Xu L, Guo Y, Wang Y, et al. Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12. Oncoimmunology. 2021;10.","DOI":"10.1080\/2162402X.2020.1868122"},{"key":"319_CR230","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae013","author":"DC Guven","year":"2024","unstructured":"Guven DC, Kavgaci G, Erul E, Syed MP, Magge T, Saeed A, et al. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review. Oncologist. 2024.https:\/\/doi.org\/10.1093\/oncolo\/oyae013","journal-title":"Oncologist"},{"key":"319_CR231","doi-asserted-by":"crossref","unstructured":"Kim K, Lee M, Shin Y, Lee Y, Kim T-J. Optimizing cancer treatment through gut microbiome modulation. Cancers (Basel) [Internet]. 2025;17. Available from: https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1252","DOI":"10.3390\/cancers17071252"},{"key":"319_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27125","author":"Y Shvets","year":"2024","unstructured":"Shvets Y, Khranovska N, Senchylo N, Ostapchenko D, Tymoshenko I, Onysenko S, et al. Microbiota substances modulate dendritic cells activity: A critical view. Heliyon. 2024.https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27125","journal-title":"Heliyon"},{"key":"319_CR233","doi-asserted-by":"publisher","DOI":"10.1007\/s11888-020-00456-1","author":"R Park","year":"2020","unstructured":"Park R, Umar S, Kasi A. Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-Augmented Clinical Trials. Curr Colorectal Cancer Rep. 2020. https:\/\/doi.org\/10.1007\/s11888-020-00456-1","journal-title":"Curr Colorectal Cancer Rep"},{"key":"319_CR234","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.10.018","author":"D Chrysostomou","year":"2023","unstructured":"Chrysostomou D, Roberts LA, Marchesi JR, Kinross JM. Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy. Gastroenterology. 2023 https:\/\/doi.org\/10.1053\/j.gastro.2022.10.018","journal-title":"Gastroenterology"},{"key":"319_CR235","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121903","author":"A Martyniak","year":"2021","unstructured":"Martyniak A, Medy\u0144ska-Prz\u0119czek A, W\u0119drychowicz A, Skocze\u0144 S, Tomasik PJ. Prebiotics, probiotics, synbiotics, paraprobiotics and postbiotic compounds in IBD. Biomolecules. 2021.https:\/\/doi.org\/10.3390\/biom11121903","journal-title":"Biomolecules"},{"key":"319_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.02.018","author":"H Luo","year":"2022","unstructured":"Luo H, Shan J, Zhang H, Song G, Li Q, Xu CX. Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer. Semin Cancer Biol. 2022.https:\/\/doi.org\/10.1016\/j.semcancer.2022.02.018","journal-title":"Semin Cancer Biol"},{"key":"319_CR237","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0526","author":"RM Connolly","year":"2017","unstructured":"Connolly RM, Rudek MA, Piekarz R. Entinostat: A promising treatment option for patients with advanced breast cancer. Future Oncology. 2017;13.https:\/\/doi.org\/10.2217\/fon-2016-0526","journal-title":"Future Oncol"},{"key":"319_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2018.12.028","author":"P Huang","year":"2019","unstructured":"Huang P, Wang X, Liang X, Yang J, Zhang C, Kong D, et al. Nano, micro, and macroscale drug delivery systems for cancer immunotherapy. Acta Biomater. 2019.https:\/\/doi.org\/10.1016\/j.actbio.2018.12.028","journal-title":"Acta Biomater"},{"key":"319_CR239","doi-asserted-by":"crossref","unstructured":"Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O\u2019Byrne K, Rezaei N, et al. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021.","DOI":"10.1002\/med.21765"},{"key":"319_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0344-8","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Shao Q, Peng G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cell Mol Immunol. 2020.https:\/\/doi.org\/10.1038\/s41423-019-0344-8","journal-title":"Cell Mol Immunol"},{"key":"319_CR241","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102461","author":"Y Fujiwara","year":"2022","unstructured":"Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, et al. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022.https:\/\/doi.org\/10.1016\/j.ctrv.2022.102461","journal-title":"Cancer Treat Rev"},{"key":"319_CR242","doi-asserted-by":"publisher","DOI":"10.4331\/wjbc.v6.i4.281","author":"E Ananieva","year":"2015","unstructured":"Ananieva E. Targeting amino acid metabolism in cancer growth and anti-tumor immune response. World J Biol Chem. 2015;6. https:\/\/doi.org\/10.4331\/wjbc.v6.i4.281","journal-title":"World J Biol Chem"},{"key":"319_CR243","doi-asserted-by":"crossref","unstructured":"Karimi S, Bakhshali R, Bolandi S, Zahed Z, Mojtaba Zadeh SS, Kaveh Zenjanab M, et al. For and against tumor microenvironment: nanoparticle-based strategies for active cancer therapy. Mater Today, Bio [Internet]. 2025;31:101626. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S259000642500184X","DOI":"10.1016\/j.mtbio.2025.101626"},{"key":"319_CR244","doi-asserted-by":"publisher","DOI":"10.7150\/thno.58390","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021.https:\/\/doi.org\/10.7150\/thno.58390","journal-title":"Theranostics"},{"key":"319_CR245","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100394","author":"KJ O\u2019Byrne","year":"2022","unstructured":"O\u2019Byrne KJ, Lee KH, Kim SW, Park K, Nishio M, Sakai H, et al. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. ESMO Open. 2022;7. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100394","journal-title":"ESMO Open"},{"key":"319_CR246","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343","author":"JA Chesney","year":"2023","unstructured":"Chesney JA, Ribas A, Long G V., Kirkwood JM, Dummer R, Puzanov I, et al. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma. Journal of Clinical Oncology. 2023;41.https:\/\/doi.org\/10.1200\/JCO.22.00343","journal-title":"J Clin Oncol"},{"key":"319_CR247","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.06.493","author":"WK Huh","year":"2020","unstructured":"Huh WK, Brady WE, Fracasso PM, Dizon DS, Powell MA, Monk BJ, et al. Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology\/gynecologic oncology group study. Gynecol Oncol. 2020;158.https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.493","journal-title":"Gynecol Oncol"},{"key":"319_CR248","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141.","DOI":"10.1182\/blood.2022018893"},{"key":"319_CR249","doi-asserted-by":"crossref","unstructured":"Bauman J, Burris H, Clarke J, Patel M, Cho D, Gutierrez M, et al. 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update. 2020.","DOI":"10.1136\/jitc-2020-SITC2020.0798"},{"key":"319_CR250","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.005","author":"VT Packiam","year":"2018","unstructured":"Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non\u2013muscle-invasive bladder cancer: Interim results. Urologic Oncology: Seminars and Original Investigations. 2018;36.https:\/\/doi.org\/10.1016\/j.urolonc.2017.07.005","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"319_CR251","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","author":"H Kantarjian","year":"2017","unstructured":"Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non\u2013muscle-invasive bladder cancer: Interim results. Urologic Oncology: Seminars and Original Investigations. 2018;36.https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"key":"319_CR252","doi-asserted-by":"crossref","unstructured":"Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, et al. Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial. JAMA Oncol. 2018;4.","DOI":"10.1001\/jamaoncol.2018.3267"},{"key":"319_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2019.02.021","author":"HK Sanoff","year":"2019","unstructured":"Sanoff HK, Moon DH, Moore DT, Boles J, Bui C, Blackstock W, et al. Phase I\/II trial of nanocamptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Nanomedicine. 2019;18.https:\/\/doi.org\/10.1016\/j.nano.2019.02.021","journal-title":"Nanomedicine"},{"key":"319_CR254","doi-asserted-by":"crossref","unstructured":"Wang J, Baidoun F, Tun HW, Alhaj Moustafa M. 90Yttrium Ibritumomab Tiuxetan (Zevalin) for the treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma: a report of 5 cases. Blood Lymphat Cancer. 2023;13.","DOI":"10.2147\/BLCTT.S398809"},{"key":"319_CR255","doi-asserted-by":"publisher","DOI":"10.1177\/10732748211038735","author":"P Pi\u00f1a-S\u00e1nchez","year":"2021","unstructured":"Pi\u00f1a-S\u00e1nchez P, Ch\u00e1vez-Gonz\u00e1lez A, Ruiz-Tachiqu\u00edn M, Vadillo E, Monroy-Garc\u00eda A, Montesinos JJ, et al. Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective. Cancer Control. 2021. https:\/\/doi.org\/10.1177\/10732748211038735","journal-title":"Cancer Control"},{"key":"319_CR256","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.08.018","author":"GW Tormoen","year":"2018","unstructured":"Tormoen GW, Crittenden MR, Gough MJ. Role of the immunosuppressive microenvironment in immunotherapy. Adv Radiat Oncol. 2018.https:\/\/doi.org\/10.1016\/j.adro.2018.08.018","journal-title":"Adv Radiat Oncol"},{"key":"319_CR257","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1166860","author":"Y Li","year":"2023","unstructured":"Li Y, Xiang S, Pan W, Wang J, Zhan H, Liu S. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective. Front Oncol. 2023.https:\/\/doi.org\/10.3389\/fonc.2023.1166860","journal-title":"Front Oncol"},{"key":"319_CR258","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e9","author":"J Choi","year":"2020","unstructured":"Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020.https:\/\/doi.org\/10.4110\/in.2020.20.e9","journal-title":"Immune Netw"},{"key":"319_CR259","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1077468","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhu Y, Xie H, Zou Z. Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2022.1077468","journal-title":"Front Pharmacol"},{"key":"319_CR260","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2019.100420","author":"L Michel","year":"2019","unstructured":"Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. IJC Heart and Vasculature. 2019.https:\/\/doi.org\/10.1016\/j.ijcha.2019.100420","journal-title":"IJC Heart Vasc"},{"key":"319_CR261","doi-asserted-by":"crossref","unstructured":"Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018","DOI":"10.1186\/s40425-018-0442-7"},{"key":"319_CR262","doi-asserted-by":"crossref","unstructured":"Zhang C, Zhang J, Tan J, Tian P, Li W. Cost-Effectiveness of Pembrolizumab for the treatment of Non\u2013Small-Cell lung cancer: A systematic review. Front Oncol. 2022","DOI":"10.3389\/fonc.2022.815587"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00319-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00319-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00319-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T23:03:14Z","timestamp":1759100594000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00319-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":262,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00319-6","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}